Orelabrutinib Combined with Pola-R-CHP Regimen Clinical Trials

1 actively recruiting trial

Also known as: Orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP)

Top Sponsors

The First Affiliated Hospital of Xiamen University1

Indications

Intermediate-High Risk1
First-Line1
DLBCL - Diffuse Large B Cell Lymphoma1
Cancer1

Other1 trial

Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.